London, UK; Brentwood, TN, US; 3 November 2006 - Protherics PLC (“Protherics” or the “Company”) and AstraZeneca today announce AstraZeneca’s intention to expand the development plan for CytoFab™, a treatment for severe sepsis, with the addition of a 480 - patient Phase II study programme.
